← All trials
NCT06488482
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Sep 30, 2030
- Completion date
- Sep 30, 2033
- First posted
- Jul 5, 2024
- Last posted
- Jul 5, 2024
- Enrollment
- 1792
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Uppsala UniversityLead sponsor
- Karolinska InstituteCollaborator
- Norrlands UniversityCollaborator
- University of GothenburgCollaborator
- Linkoping UniversityCollaborator
- Orebro UniversityCollaborator
- Karlstad UniversityCollaborator
- Gävle HospitalCollaborator
- Falu HospitalCollaborator
- Lund UniversityCollaborator
- Uppsala UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.